Lightnews — Scholar-powered news

Gemma Salvadó @gsalvado.bsky.social · 20d

🚨Postdoc position open at @BarcelonaBeta🚨
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ

www.imim.cat

8 4

Gemma Salvadó @gsalvado.bsky.social · 21d

Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals.
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET

biofinder.bsky.social @biofinder.bsky.social · 23d

🚨Paper alert🚨
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.

jamanetwork.com/journals/jam...

A 🧵...

Plasma P-Tau217 to Identify Preclinical AD

This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.

jamanetwork.com

Gemma Salvadó @gsalvado.bsky.social · 27d

Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease .

Great resource to be up to date!

Julie Ottoy @ottoyjulie.bsky.social · 29d

🔥Recent advances in #neuroimaging of #Alzheimers disease 🧠✨

dx.doi.org/10.1002/alz....

➡️ Valuable resource for both researchers & clinicians!
➡️ ATNIV biomarkers, staging, connectomics & more
➡️ Plus: how are sex & country represented in first/last authorship?

@istaart.bsky.social Neuroimaging PIA

2

Reposted by Gemma Salvadó

BrightFocus Foundation @brightfocus.bsky.social · Aug 29

A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression—not just diagnosis.

BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.

🔬 Full story ⬇️

New Blood Test Could Personalize Alzheimer's Treatment Like Never Before

A new Alzheimer's blood test may reveal how far the disease has progressed and identify who's most likely to benefit from anti-amyloid therapies.

www.brightfocus.org

2 2

Gemma Salvadó @gsalvado.bsky.social · Aug 23

New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ

biofinder.bsky.social @biofinder.bsky.social · Aug 22

🚨New publication in Nature Aging🚨
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵

Plasma tau biomarkers for biological staging of Alzheimer’s disease - Nature Aging

Montoliu-Gaya, Salvadó et al. develop a blood-based model using tau biomarkers measured in a single analysis enabling biological staging of Alzheimer’s disease to support the diagnosis, prognosis and ...

nature.com

1

Gemma Salvadó @gsalvado.bsky.social · Jul 30

Super proud of @noellewarmenhoven.bsky.social !
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦

4

Gemma Salvadó @gsalvado.bsky.social · Jul 28

Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025

1 1

Gemma Salvadó @gsalvado.bsky.social · Jul 27

Outstanding plenary presentation by @sylviavilleneuve.bsky.social today on preclinical #Alzheimer’s disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research.
#AAIC2025

1 6

Gemma Salvadó @gsalvado.bsky.social · Jul 27

Powerful words from Cliff Jack as he accepted his lifetime achievement award.
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025

7

Gemma Salvadó @gsalvado.bsky.social · Jul 27

If you're at #AAIC2025, don't miss the great work by @wiesjepelkmans.bsky.social !

Wiesje Pelkmans @wiesjepelkmans.bsky.social · Jul 27

Excited to be back at #AAIC2025! We already had a great start with an inspiring Imaging day yesterday. On Monday, I’ll present our work on how #microglial reactivity influences very early #amyloid accumulation on #PET. Come by poster 364 if you’d like to know more!

1 3

Gemma Salvadó @gsalvado.bsky.social · Jul 26

What a plenary!
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦

7

Gemma Salvadó @gsalvado.bsky.social · Jul 9

🚨 Heading to @EANM_NucMed meeting in Barcelona this fall?
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers

Barcelonaβeta Brain Research Center @barcelonabeta.bsky.social · Jul 9

We have a date on October 7!🧠

We are organising the event "Clinical Use of PET in Alzheimer's Disease: Challenges & Opportunities"

We'll bring together experts in the field of nuclear medicine and #Alzheimer's to explore the latest developments in PET imaging techniques.

2

Gemma Salvadó @gsalvado.bsky.social · Jun 21

Yesterday, @anikawuestefeld.bsky.social brilliantly defended her PhD thesis on the fole of MTL in Alzheimer’s disease.
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏

6

Reposted by Gemma Salvadó

biofinder.bsky.social @biofinder.bsky.social · May 5

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/

1 2 2

Reposted by Gemma Salvadó

Laura Wisse @lemwisse.bsky.social · Apr 23

Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!

Nos super offres || PhD - polypathology in the medial temporal lobe

offres.institutducerveau-icm.org

1 5 3

Gemma Salvadó @gsalvado.bsky.social · Apr 9

Important work from @biofinder.bsky.social and @barcelonabeta.bsky.social groups!

biofinder.bsky.social @biofinder.bsky.social · Apr 9

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵

Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine

Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.

nature.com

Reposted by Gemma Salvadó

La Vanguardia @lavanguardia.com · Apr 9

🔵🔬El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre. El test ya está a punto para utilizarse de manera rutinaria en los hospitales, y no solo con fines de investigación como hasta ahora.

www.lavanguardia.com/ciencia/2025...

El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre

Un análisis de sangre permite diagnosticar la mayoría de casos de alzheimer de manera precoz, cuando los afectados tienen síntomas incipientes de deterioro cognitivo,

www.lavanguardia.com

6 47 140

Gemma Salvadó @gsalvado.bsky.social · Apr 1

If you're at #ADPD25 you can go to biomarkers, imaging and translational aspects in Hall A for a live presentation by Kanta Horie (14:45 CET)

Gemma Salvadó @gsalvado.bsky.social · Apr 1

Proud to be part of this important collaboration with Kanta Horie and Randall Bateman from Washington University in St. Louis and Oskar Hansson from @biofinder.bsky.social among many others!

1

Gemma Salvadó @gsalvado.bsky.social · Apr 1

Huge development towards a precise and scalable diagnosis of #Alzheimer's disease.

Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients

biofinder.bsky.social @biofinder.bsky.social · Mar 31

‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social:
📖 www.nature.com/articles/s41...

In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease - Nature Medicine

Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

www.nature.com

1 3

Reposted by Gemma Salvadó

biofinder.bsky.social @biofinder.bsky.social · Feb 26

🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600

PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇

Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data

INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...

doi.org

1 1 2

Gemma Salvadó @gsalvado.bsky.social · Feb 25

Incredible plenary presentation by @rikossenkoppele.bsky.social at AAIC Neuroscience Next in Barcelona! Ending on a hopeful note for the future of #Alzheimer's research and therapeutics.

6

Gemma Salvadó @gsalvado.bsky.social · Feb 6

Thrilled to be back home at BBRC & Fundació Pasqual Maragall as the Lead of the Neuroimaging Group! 🎉
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl

https://www.barcelonabeta.org/es/centro-investigacion-bbrc/ofertas-empleo/phd-student-position-neuroimaging-group-barcelonabeta

t.co

2 4

Reposted by Gemma Salvadó

biofinder.bsky.social @biofinder.bsky.social · Jan 20

A new The Swedish BioFINDER study paper in collaboration with WRAP has been published in
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta

Cicognola et al. investigate the relationship between the APOE4 gene—the strongest genetic risk factor for Alzheimer’s disease—and tau. They find that the

academic.oup.com

1 1

Gemma Salvadó @gsalvado.bsky.social · Jan 18

Such an honour to receive the young investigator award from my favourite conference.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.

2 12